In October, FDA approved two new drugs, nintedanib (Ofev, Boehringer Ingelheim) and pirfenidone (Esbriet, InterMune), to help manage idiopathic pulmonary fibrosis (IPF).
Medscape Advisory Board member for Pulmonary Medicine, Steven Nathan, MD, was a principal investigator in studies on pirfenidone and nintedanib and spoke with Medscape about the importance of the new drug approvals, how the drugs work, and how physicians might use them to potentially extend the lives of their patients.
